Navigation Links
WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
Date:4/28/2008

SHANGHAI, China, April 28 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has been listed among "The BCG 50 Local Dynamos" by The Boston Consulting Group (BCG).

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

BCG defines local dynamos as companies from rapidly developing economies (RDEs) that remain local and use truly innovative business models to conquer their domestic markets. BCG has identified six key success factors that distinguish these 50 local dynamos from their less successful competitors. These six factors are: customizing to local needs, devising innovative business models that overcome local challenges, leveraging the latest technologies, benefiting from low-cost labor and overcoming shortages of skilled labor, scaling up fast and sustaining long-term hyper growth without imploding.

Among the 50 local dynamos, 15 are from China and WuXi PharmaTech is the only winner in the health care industry. Other China-based winners include Baidu.com, Ctrip.com International, Focus Media, New Oriental Education and Technology Group, and Shanda Interactive Entertainment.

"We chose companies mainly based on their having an innovative business model," commented David Michael, the report's coauthor, Partner and Managing Director of BCG Greater China.

"We are very pleased and honored to be one of The 50 Local Dynamos by BCG. With a vision to transform the global drug and medical device R&D model, WuXi PharmaTech is building a global R&D service platform that serves pharmaceutical, biotechnology and medical device companies worldwide," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We will continue our unremitting efforts to better serve clients and create value for our shareholders."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com.

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical ... Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to a ... in a group of 20 patients carrying 11778, 14484 and 3460 mutations and having ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... on capillary thermal mass flow technology provide exponentially more accurate mass flow data ... 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, ...
(Date:4/27/2017)... NASHVILLE, Tenn. , April 27, 2017  Pendant ... company developing innovative surface modification and drug delivery technologies, ... & Johnson Innovation, JLABS @ Toronto ... Chief Executive Officer of Pendant Biosciences, noted, "We are ... Toronto community, and are honored to ...
(Date:4/26/2017)... Alto, CA, USA (PRWEB) , ... April 26, ... ... popular seminar on FDA’s GMP expectations for phase I clinical trials comes to ... attended by various biotechnology and pharma professionals representing FDA regulated organizations such as ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):